B
Byron E. E. Martina
Researcher at Artemis
Publications - 126
Citations - 6609
Byron E. E. Martina is an academic researcher from Artemis. The author has contributed to research in topics: Virus & Dengue virus. The author has an hindex of 35, co-authored 118 publications receiving 5650 citations. Previous affiliations of Byron E. E. Martina include University Hospital of Basel & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Dengue Virus Pathogenesis: an Integrated View
TL;DR: A personalized approach to the study of pathogenesis will elucidate the basis of individual risk for development of DHF and DSS as well as identify the genetic and environmental bases for differences in risk forDevelopment of severe disease.
Journal ArticleDOI
Virology: SARS virus infection of cats and ferrets.
Byron E. E. Martina,Bart L. Haagmans,Thijs Kuiken,Ron A. M. Fouchier,Guus F. Rimmelzwaan,Geert van Amerongen,J. S. Malik Peiris,Wilina Lim,Albert D. M. E. Osterhaus +8 more
TL;DR: It is shown that ferrets and domestic cats are susceptible to infection by SARS coronavirus (SCV) and that they can efficiently transmit the virus to previously uninfected animals that are housed with them.
Journal ArticleDOI
Influenza B Virus in Seals
Albert D. M. E. Osterhaus,Guus F. Rimmelzwaan,Byron E. E. Martina,Theo M. Bestebroer,Ron A. M. Fouchier +4 more
TL;DR: In this article, an influenza B virus was isolated from a naturally infected harbor seal (Phoca vitulina) and was found to be infectious to seal kidney cells in vitro Sequence analyses and serology indicated that influenza virus B/Seal/Netherlands/1/99 is closely related to strains that circulated in humans 4 to 5 years earlier.
Journal ArticleDOI
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Bart L. Haagmans,Thijs Kuiken,Byron E. E. Martina,Ron A. M. Fouchier,Guus F. Rimmelzwaan,Geert van Amerongen,Debby van Riel,Ton de Jong,Shigeyuki Itamura,Kwok-Hung Chan,Masato Tashiro,Albert D. M. E. Osterhaus +11 more
TL;DR: It is suggested that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy.
Journal ArticleDOI
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
Berend Jan Bosch,Byron E. E. Martina,Ruurd van der Zee,Jean Lepault,Bert Jan Haijema,Cees Versluis,Albert J. R. Heck,Raoul J. de Groot,Albert D. M. E. Osterhaus,Peter J. M. Rottier +9 more
TL;DR: The inhibitory potency of the SARS-CoV HR2-peptides provides an attractive basis for the development of a therapeutic drug for SARS.